- Home
- GLPI vs BBIO Comparison
GLPI vs BBIO Comparison
Compare GLPI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPI | BBIO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 14.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GLPI | BBIO |
|---|---|---|
| Price | $41.95 | $73.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $51.88 | ★ $74.79 |
| AVG Volume (30 Days) | ★ 2.3M | 2.1M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 7.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.79 | N/A |
| Revenue | ★ $1,577,336,000.00 | $353,780,000.00 |
| Revenue This Year | $5.71 | $128.44 |
| Revenue Next Year | $4.63 | $76.14 |
| P/E Ratio | $15.02 | ★ N/A |
| Revenue Growth | 4.39 | ★ 62.46 |
| 52 Week Low | $41.78 | $25.34 |
| 52 Week High | $52.25 | $75.04 |
Technical Indicators
Market Signals| Indicator | GLPI | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 71.15 |
| Support Level | $42.99 | $71.16 |
| Resistance Level | $43.90 | $75.04 |
| Average True Range (ATR) | 0.71 | 2.48 |
| MACD | -0.07 | 0.27 |
| Stochastic Oscillator | 3.72 | 88.13 |
Price Performance
Historical ComparisonAbout GLPI Gaming and Leisure Properties Inc.
Gaming and Leisure Properties Inc, or GLP, is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). It is engaged in acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. Its portfolio consists of gaming and related facilities and amenities such as Ameristar Black Hawk, Bally's Casino, Argosy Casino Alton, Bally's Chicago, Hollywood Casino Aurora, and others located across different states in the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.